###begin article-title 0
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lysyl oxidase-like protein 1</italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Lysyl oxidase-like protein 1 (LOXL1) gene polymorphisms and exfoliation glaucoma in a Central European population
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 283 311 283 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lysyl oxidase-like protein 1</italic>
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 557 562 557 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 614 622 <span type="species:ncbi:9606">patients</span>
Exfoliation syndrome (XFS) is characterized by an accumulation of abnormal extracellular material in the anterior part of the eye that frequently leads to increased intraocular pressure and glaucomatous optic neuropathy. Recently, two non-synonymous polymorphisms ( G>T and  G>A) of lysyl oxidase-like protein 1 (LOXL1), a monoamine oxidase that catalyzes the polymerization of tropoelastin to elastin, were found to be associated with increased risk for XFS and exfoliation glaucoma (XFG). The aim of the present study was to investigate the role of these LOXL1 variants in a Central European cohort of Caucasian patients with XFG.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
The present case-control study comprised of 167 unrelated patients with XFG and 170 control subjects. Genotyping of the LOXL1 and  polymorphisms was done using polymerase chain reaction.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
The frequency of allele G of  as well as  was significantly higher in patients than in controls (: 0.841 in patients versus 0.669; p<0.001; : 0.994 in patients versus 0.817; p<0.001). Odds ratios of 52.1 (95% confidence interval [CI]: 13.85-195.6) and 14.67 (95% CI: 3.81-56.2), respectively, were calculated for the two high-risk haplotypes GG and TG compared to the haplotype GA.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Our data confirm the previously reported association between LOXL1 polymorphisms and XFG and extend our knowledge to a Central European population.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 614 615 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
Exfoliation syndrome (XFS; OMIM ) is characterized by an accumulation of abnormal extracellular fibrillar material not only in different structures of the eye but also in various extraocular tissues [1]. Therefore, XFS has been suggested to be a generalized elastic fibrillopathy. Exfoliation fibrils are highly characteristic and consist of a protein core including components of basement membrane and the elastic fiber system surrounded by glycoconjugates [2]. Prevalence of XFS varies widely with the highest prevalence in the Nordic European countries (up to 25%) and 5%-15% in Central European populations [2,3].
###end p 11
###begin p 12
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
Clinically, exfoliation material is recognized as a whitish material on the anterior capsule of the lens and flakes at the pupillary border. Secondary open-angle glaucoma due to XFS (exfoliation glaucoma, XFG) develops as a consequence of deposition of exfoliation material and of liberated iris pigment in the trabecular meshwork leading to elevated intraocular pressure and consecutively glaucomatous optic neuropathy [4].
###end p 12
###begin p 13
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
The exact cause for the production of the exfoliation material is still elusive, but there is ample evidence that genetic factors may contribute to the pathogenesis of XFS. Various family-based studies reported a higher frequency of XFS among relatives of patients with XFS [5-8]. Furthermore, increased rates of loss of heterozygosity have been found in specimens of the anterior segment in individuals with XFS, suggesting genetic factors play a role in the pathogenesis of the disease [9].
###end p 13
###begin p 14
###xml 191 219 191 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lysyl oxidase-like protein 1</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Most importantly, a recent genome-wide association study from Icelandic and Swedish patients with XFS and XFG found two common non-synonymous single nucleotide polymorphisms in exon 1 of the lysyl oxidase-like protein 1 gene (LOXL1; OMIM ) conferring increased risk for the development of XFS and XFG ( and ) [10].  induces an amino acid change from arginine to leucine at position 141 (R141L) whereas  induces an amino acid change from glycine to asparagine at position 153 (G153D).
###end p 14
###begin p 15
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
So far, the potential role of these polymorphisms has not yet been determined in a Central European population. Therefore, our study was set to investigate the aforementioned LOXL1 variants in a Central European cohort of Caucasian origin.
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 150 162 <span type="species:ncbi:9606">participants</span>
###xml 244 256 <span type="species:ncbi:9606">Participants</span>
One hundred sixty-seven unrelated patients with XFG and 170 control subjects were enrolled in the present retrospective case-control study. All study participants were Caucasians from the same geographical area in the southern part of Austria. Participants were seen at the Department of Ophthalmology, Medical University of Graz, Graz, Austria between May 2003 and April 2007 and gave informed, written consent before enrollment. The study was conducted in accordance with the National Gene Technology Act of Austria and the guidelines of the local ethics committee.
###end p 17
###begin p 18
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 491 503 <span type="species:ncbi:9606">participants</span>
Patients with XFG underwent slit lamp biomicroscopy in mydriasis, testing for best corrected visual acuity, Goldmann applanation tonometry, gonioscopy, pachymetry, and standard automated perimetry (Octopus 101, programme G2; Interzeag, Bern, Switzerland) or - in cases of profoundly decreased visual acuity - Goldmann perimetry. Control subjects underwent slit lamp biomicroscopy in mydriasis, Goldmann applanation tonometry, and testing for best corrected visual acuity. Optic discs in all participants were assessed by glaucoma specialists (C.F. and G.M.).
###end p 18
###begin p 19
XFG was defined by the presence of typical exfoliation material on the anterior lens capsule, an intraocular pressure of at least 22 mmHg before initiation of a pressure-lowering therapy, an open anterior chamber angle, optic disc changes characteristic for glaucoma (notching, thinning of the neuroretinal rim, and increased cup/disc ratio in relation to the optic disc size), visual field defects characteristic for glaucoma (inferior or superior arcuate scotoma, nasal step, and paracentral scotoma), and the absence of conditions leading to secondary glaucoma.
###end p 19
###begin p 20
Control subjects showed biomicroscopically no evidence of exfoliation material on the anterior capsule of the lens and no morphological damage indicative for open-angle or angle closure glaucoma. Control subjects were admitted to our department for cataract surgery.
###end p 20
###begin title 21
Genotype determination
###end title 21
###begin p 22
###xml 162 167 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Genomic DNA was extracted from peripheral blood lymphocytes by standard techniques and stored at -70 degreesC until genotype determination. For genotyping of the LOXL1 R141L polymorphism, a 179 base-pair segment containing the polymorphic site was amplified by polymerase chain reaction using forward primer 5'-GCC GTC GGG GAC AGC A-3' and reverse primer 5'-TAG TTC TCG TAC TGG CTG ACG AA-3'. Amplified products were digested with restriction enzyme SmaI (New England Biolabs, Frankfurt, Germany). The 141R allele was cut into two fragments of 151 and 28 base pairs whereas the 141L allele remained uncut. Fragments were separated on 2.5% agarose gels and visualized by use of ethidium bromide.
###end p 22
###begin p 23
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
The LOXL1 G153D polymorphism was determined by a 5'-exonuclease assay (TaqMan; Applied Biosystems, Vienna, Austria) using forward primer 5'-ACC TCC GTC TCC CAG CAA-3', reverse primer 5'-TGC TGG CGA AGG CCG AAG-3', LOXL1-153G-probe VIC-CGG AGC CCC CGT G-NFQ, and LOXL1-153D-probe FAM-AGG CGG AGT CCC CGT-NFQ (Applied Biosystems, Vienna, Austria). The assay was performed according to the manufacturer's instructions, and end-point fluorescence was measured in a lambda Fluoro 320 plus plate reader (MWG Biotech AG, Ebersberg, Germany) using excitation/emission filters of 485/530 nm and 530/572 nm, respectively. The data were exported into Excel format and depicted and analyzed as a scatter plot.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 253 254 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 685 687 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
Descriptive statistics were used to calculate frequencies and percentages of discrete variables. Continuous data are given as mean+/-standard deviation (SD). Means were compared using the Mann-Whitney test. Proportions of groups were compared by the chi2 test. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated by logistic regression. The criterion for statistical significance was p</=0.05. The Hardy-Weinberg (HW) equilibrium has been calculated using HW Diagnostics-Version 1.beta (Fox Chase Cancer Center, Philadelphia, PA). Statistical analysis was done using the SPSS statistical package (SPSS v14.0, Chicago, Illinois) and haplotype analysis was done using  [11].
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 377 378 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">Patients</span>
The present study comprised 167 patients with XFG (91 female, 76 male) and 170 control subjects (95 female, 75 male). The mean age of patients with XFG was 75.7 years (range 50.3-91.6 years), and the mean age of control subjects was 77.1 years (range 58.9-92.7 years). Patients with XFG had a mean deviation of 13.0+/-6.9 decibel (dB), a mean loss of variance of 36.7+/-21.5 dB2, a mean intraocular pressure of 26.0+/-11.2 mmHg, and a mean cup disc ratio of 0.80+/-0.16 in the worse eye.
###end p 27
###begin p 28
###xml 170 177 170 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
The success rate of genotyping was 93.5% for  and 94.1% for . The observed genotype distributions did not deviate from those predicted by the Hardy-Weinberg equilibrium. Table 1 shows the genotype and allele frequencies of  and  in patients with XFG and control subjects. In both polymorphisms, the prevalence of the GG genotype as well as the frequency of allele G was significantly higher in patients with XFG than in control subjects. An odds ratio of 2.69 (95% CI: 1.59-4.54) was calculated for allele G of . For allele G of , an odds ratio of 37.29 (95% CI: 6.35-218.02) was calculated.
###end p 28
###begin title 29
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies of  and  in patients with exfoliation glaucoma and control subjects.
###end title 29
###begin p 30
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 203 204 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies of  and  in exon 1 of LOXL1 in Central European patients with exfoliation glaucoma versus Central European control subjects. Proportions of groups were compared by the chi2 test. Numbers for genotypes are n (%).
###end p 30
###begin p 31
###xml 128 135 128 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
The two variants are in strong linkage disequilibrium (D'=1.0), and only three possible haplotypes were observed in our cohort (Table 2). Compared to the protective haplotype GA, the GG haplotype conferred an odds ratio of 52.1 (95% CI: 13.85-195.6) while the TG haplotype conferred an odds ratio of 14.67 (95% CI: 3.81-56.2).
###end p 31
###begin title 32
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Frequencies of LOXL1 haplotypes in patients with exfoliation glaucoma and control subjects.
###end title 32
###begin p 33
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 238 239 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Frequencies of haplotypes of  and  in exon 1 of LOXL1 in Central European patients with exfoliation glaucoma versus Central European control subjects. Haplotype analysis was performed using . Proportions of groups were compared by the chi2 test. Numbers for haplotypes are n (%).
###end p 33
###begin p 34
Positive likelihood ratio and negative likelihood ratio were 1.26 and 0.47, respectively, for allele G of . For allele G of , positive likelihood ratio and negative likelihood ratio were 1.22 and 0.03, respectively.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 327 328 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 329 330 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 599 601 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 602 604 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 932 934 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 991 998 988 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">elastin</italic>
###xml 1003 1031 1000 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lysyl oxidase-like protein 2</italic>
###xml 1086 1088 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 769 773 <span type="species:ncbi:10090|species:ncbi:10095">Mice</span>
Mainstay of the pathogenesis of exfoliation syndrome is the accumulation of pathognomonic fibrils in the anterior segment of the eye as well as in extraocular locations [1]. These fibrils are partly composed of components of the elastic fiber system like elastin, tropoelastin, amyloid P, and latent TGF-beta binding proteins [2,4]. As a monoamine oxidase secreted by fibrogenic cells, LOXL1 catalyzes the deamination of lysyl residues of tropoelastin, the monomeric form of elastin. This deamination leads to the polymerization of tropoelastin to elastin, which is the first step of elastogenesis [12,13]. Therefore, it is biologically plausible that an altered function of one of the key enzymes of elastogenesis leads to an increased susceptibility for XFS and XFG. Mice lacking LOXL1 display tropoelastin accumulation in multiple tissues, which leads to pelvic organ prolapse, emphysematous changes, and vascular abnormalities [13]. Interestingly, regarding primary open-angle glaucoma, elastin and lysyl oxidase-like protein 2 has been suggested as candidate susceptibility genes [14].
###end p 36
###begin p 37
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 619 626 619 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
###xml 972 980 <span type="species:ncbi:9606">patients</span>
The present study being the first in a Central European population confirms the strong association between LOXL1 variants and XFG. Beside the original study from Thorleifsson and coworkers [10] that included an Icelandic and a Swedish cohort, four studies from the United States, one study from Australia, one study from Japan, and one from India investigating LOXL1 polymorphisms in XFS and XFG have been performed [10,15-21]. The prevalence of allele G of  and  found in the present study were remarkably similar to four of these studies [14-16] while in three studies, slightly lower prevalences have been reported (Table 3) [18-20]. This fact may be due to greater ethnic heterogeneity of the investigated populations or different additional genetic or environmental risk factors. It is noteworthy that in the study from Japan, no allele G in  was detected in patients with XFG while frequency of allele G in  was found to be 100% in their study [21]. In contrast, in patients with XFG in our cohort frequencies of the G alleles of  and  was 84.1% and 99.4%, respectively, pointing towards significant differences in the prevalence of rs1048661 among different ethnicities.
###end p 37
###begin title 38
Distribution of frequencies and odds ratios of  and  among different populations.
###end title 38
###begin p 39
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Presented are allele frequencies and odds ratios of the G-allele of  and  in exon 1 of LOXL1 in patients with exfoliation syndrome and exfoliation glaucoma among different populations including the present study. The asterisk indicates numbers for  and the double asterisk indicates numbers for ; ND=not determined.
###end p 39
###begin p 40
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
With positive and negative likelihood ratios of 1.26 and 0.47 (allele G of ) and 1.22 and 0.03 (allele G of ), respectively, genetic testing for XFG based solely on these polymorphisms of LOXL1 can not be recommended.
###end p 40
###begin p 41
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
In conclusion, the results of our study demonstrate the importance of the LOXL1 polymorphisms in a Central European population of Caucasian origin. As other genetic or environmental factors are likely to be involved in the pathogenesis of XFG, further studies are warranted.
###end p 41
###begin title 42
Acknowledgements
###end title 42
###begin p 43
The authors thank Ms. Trummer and Ms. Wachswender for their skillful technical assistance.
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder?
###end article-title 45
###begin article-title 46
Exfoliation syndrome.
###end article-title 46
###begin article-title 47
Epidemiology of the pseudo-exfoliation syndrome.
###end article-title 47
###begin article-title 48
Why is glaucoma associated with exfoliation syndrome?
###end article-title 48
###begin article-title 49
Is pseudoexfoliation syndrome inherited? A review of genetic and nongenetic factors and a new observation.
###end article-title 49
###begin article-title 50
Exfoliation syndrome: clinical and genetic features.
###end article-title 50
###begin article-title 51
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Early diagnosis of exfoliation syndrome in the offspring of affected patients.
###end article-title 51
###begin article-title 52
Pseudoexfoliation syndrome in Icelandic families.
###end article-title 52
###begin article-title 53
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Loss of heterozygosity in patients with pseudoexfoliation syndrome.
###end article-title 53
###begin article-title 54
Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma.
###end article-title 54
###begin article-title 55
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 55
###begin article-title 56
The Pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers.
###end article-title 56
###begin article-title 57
Elastic fiber homeostasis requires lysyl oxidase-like 1 protein.
###end article-title 57
###begin article-title 58
Population differences in elastin maturation in optic nerve head tissue and astrocytes.
###end article-title 58
###begin article-title 59
###xml 60 68 <span type="species:ncbi:9606">patients</span>
LOXL1 mutations are associated with exfoliation syndrome in patients from the midwestern United States.
###end article-title 59
###begin article-title 60
Genetic association of LOXL1 gene variants and exfoliation glaucoma in a Utah cohort.
###end article-title 60
###begin article-title 61
DNA sequence variants in the LOXL1 gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity.
###end article-title 61
###begin article-title 62
###xml 138 144 <span type="species:ncbi:9606">people</span>
Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people.
###end article-title 62
###begin article-title 63
Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma.
###end article-title 63
###begin article-title 64
Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India.
###end article-title 64
###begin article-title 65
Lysyl Oxidase-like 1 Polymorphisms and Exfoliation Syndrome in the Japanese Population.
###end article-title 65

